Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.45 EPS (ttm)10.56 Insider Own0.20% Shs Outstand737.00M Perf Week5.20%
Market Cap127.99B Forward P/E13.62 EPS next Y12.75 Insider Trans-0.45% Shs Float734.34M Perf Month11.74%
Income7.89B PEG3.92 EPS next Q3.10 Inst Own80.70% Short Float1.10% Perf Quarter5.31%
Sales22.93B P/S5.58 EPS this Y13.10% Inst Trans0.07% Short Ratio2.31 Perf Half Y18.66%
Book/sh41.57 P/B4.18 EPS next Y2.52% ROA10.20% Target Price180.79 Perf Year18.59%
Cash/sh52.10 P/C3.33 EPS next 5Y4.20% ROE26.00% 52W Range133.64 - 184.21 Perf YTD18.78%
Dividend4.60 P/FCF18.60 EPS past 5Y20.50% ROI13.00% 52W High-5.72% Beta1.37
Dividend %2.65% Quick Ratio4.10 Sales past 5Y8.10% Gross Margin81.90% 52W Low29.95% ATR2.79
Employees19200 Current Ratio4.40 Sales Q/Q-1.10% Oper. Margin43.50% RSI (14)73.19 Volatility2.15% 1.59%
OptionableYes Debt/Eq1.11 EPS Q/Q11.80% Profit Margin34.40% Rel Volume0.86 Prev Close172.50
ShortableYes LT Debt/Eq0.99 EarningsJul 26 AMC Payout39.00% Avg Volume3.51M Price173.67
Recom2.40 SMA206.62% SMA507.49% SMA2008.28% Volume3,031,353 Change0.68%
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Jun-26-17 11:35AM  Regeneron: The End of the Outperformance?
Jun-23-17 04:00PM  Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis PR Newswire
09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
Jun-22-17 03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
03:00PM  Drugmakers May Lose $390B In Sales Over 5 Years Investopedia
12:22PM  Health-Care Stocks Get a Boost From Senate Bill Rollout The Wall Street Journal
08:00AM  Today's Research Reports on Stocks to Watch: Amgen and Incyte Accesswire
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 03:00PM  Amgen An Undervalued Industry Leader Forbes
01:52PM  Here's where big oil companies feel the pain of lower crude prices: NYSE trader Yahoo Finance Video
01:52PM  Drug stocks rally after Trump decides no price controlsyet: NYSE trader Yahoo Finance Video
12:05PM  Here are the biotech stocks the traders are buying CNBC Videos
11:51AM  Amgen Defends Drug Pipeline, Says the Best is Yet to Come
11:16AM  Novartis Migraine Drug Accepted, AMD Positive in Phase III Zacks
10:35AM  Amgen: In Defense of A Pipeline
09:00AM  Amgen To Present New Data At 22nd Congress of the European Hematology Association PR Newswire
08:30AM  Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt Zacks
Jun-20-17 06:05PM  Why Pomalyst Could See Significant Revenue Growth in 2017 Market Realist
03:36PM  Updates on the Adcetris and Opdivo Combination Market Realist
03:31PM  3 Dividend Stocks for Long-Term Investors Motley Fool
11:18AM  Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA Zacks
09:55AM  Worldwide drug sale forecasts fall as pricing pressures mount Reuters
09:06AM  Analyzing Eli Lillys Collaboration with KeyBioscience AG Market Realist
07:27AM  5 Most Profitable Big Pharma Stocks on the Market Right Now Motley Fool
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here"
10:28AM  AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run? Zacks
09:00AM  FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients PR Newswire
08:24AM  3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper) Motley Fool
Jun-18-17 11:01AM  AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher Motley Fool
Jun-17-17 03:06PM  The Supreme Court Just Made a Big Opportunity for Biosimilars Even Bigger Motley Fool
Jun-16-17 12:47PM  2 Incredibly Cheap Biotech Stocks Motley Fool
09:30AM  Is Amgen (AMGN) a Great Stock for Value Investors? Zacks
07:23AM  Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact" Reuters
Jun-15-17 10:36AM  Analysts Recommendations for AbbVie in June 2017 Market Realist
08:26AM  Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug Zacks
Jun-13-17 09:37AM  Amgen's Multiple Myeloma Drug Receives NICE Recommendation Zacks
Jun-12-17 07:01PM  Amgen's Multiple Myeloma Treatment, KYPROLIS® (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse PR Newswire
05:55PM  Copycat 'biosimilars' win fast track, but FDA says this Bay Area company must slow down American City Business Journals
04:28PM  Theres a race to treat a condition that affects 38 million Americans heres what you need to know Business Insider
04:07PM  Coherus Dives To Year-Low After Amgen-Rivaling Drug Sees Delay Investor's Business Daily
12:51PM  U.S. Supreme Court speeds copycat biologic drugs to market Reuters
12:43PM  High court ruling speeds up generic biotech drug approval Associated Press
11:25AM  Regeneron: Forget Praluent. This Is the Drug That Really Matters.
11:01AM  FDA rejects Coherus's biosimilar for Neulasta, shares plunge Reuters
10:59AM  FDA rejects Coherus's biosimilar for Neulasta, shares plunge Reuters
10:34AM  Why Coherus Biosciences Stock Is Getting Hammered Today Motley Fool
10:34AM  U.S. Supreme Court Issues Mixed Ruling on Biotech-Drug Copies Bloomberg
09:40AM  Short Interest Surges in Major Biotechs 24/7 Wall St.
08:49AM  Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies Zacks
06:51AM  FDA rejects Coherus's biosimilar for Amgen's Neulasta Reuters
Jun-09-17 02:08PM  Amgen, Inc. Value Analysis (NASDAQ:AMGN) : June 9, 2017 Capital Cube
01:43PM  Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags
01:33PM  We Deliver: SBUX, AMGN, and more CNBC Videos
12:02PM  New migraine drugs have promise and a $8,500 price tag MarketWatch
Jun-08-17 04:30PM  Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society PR Newswire
04:20PM  How This Small Biotech Could Ruffle The Market In Migraine Drugs Investor's Business Daily
04:00PM  Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference PR Newswire
10:05AM  Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit Zacks
08:08AM  Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : June 8, 2017 Capital Cube
Jun-07-17 04:46PM  Amgen Wants to Boost Label on Powerhouse Repatha
04:22PM  Will Regeneron's Cholesterol-Buster Get Booted In Amgen Battle? Investor's Business Daily
11:40AM  Amgen: It Could Win The Latest Patent Battle; Will It Matter?
09:00AM  Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab PR Newswire
Jun-06-17 05:41PM  Regeneron, Sanofi urge court to reverse ban on cholesterol drug Reuters
04:26PM  3 Value Stocks Perfect for Retirement Motley Fool
04:09PM  Amgen Files for Repatha in the U.S., EU for Expanded Use Zacks
03:03PM  Regeneron vs Amgen: Does The Patent Battle Even Matter?
12:16PM  Perrigo: As the Revolving Door Spins
Jun-05-17 01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
12:44PM  Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs Zacks
12:18PM  Chart points to explosive breakout for 'the No. 1 stock ever': Technician CNBC
09:00AM  Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe PR Newswire
Jun-04-17 10:45AM  Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 PR Newswire
Jun-03-17 05:45PM  Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017 PR Newswire
Jun-02-17 04:00PM  Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge PR Newswire
Jun-01-17 08:02AM  Has The Final Piece To Eliminate Heart Disease Been Discovered? Probably Not Forbes
May-31-17 04:25PM  Teva Pharma Ran A Migraine Trial And Lilly, Amgen Benefited Investor's Business Daily
09:15AM  How Regeneron Pharmaceuticals, Inc. Makes Most of Its Money Motley Fool
May-30-17 01:43PM  Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc. PR Newswire
08:58AM  Tracking The Busy June PDUFA Calendar Benzinga
08:43AM  Millennial stock picks you may have missed CNBC Videos
07:49AM  Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug Zacks
07:23AM  The 5 Best Dividend Stocks in Cholesterol Drugs Motley Fool
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
04:20AM  Amgen (AMGN) Down 4.5% Since Earnings Report: Can It Rebound? Zacks
May-27-17 07:26AM  3 Dividend Stocks That Thrive in Market Crashes Motley Fool
May-26-17 12:15PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amgen Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:30AM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Amgen Inc. Investors Business Wire
09:36AM  Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote Zacks
07:36AM  Nplate and Vectibix Could Contribute to Amgens Revenue Growth in 2017 Market Realist
May-25-17 07:09PM  [$$] Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment The Wall Street Journal
12:23PM  These 5 Healthcare Stocks Are Undervalued Forbes
10:36AM  Could There Be a Revenue Fall for Neulasta in 2017? Market Realist
10:29AM  A Look At Nvidia's Largest Shareholders And What Their Presence Means Benzinga
09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St.
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene Zacks
09:24AM  Radius Health Osteoporosis Drug Positive in Phase III Study Zacks
09:06AM  Exploring Kyproliss Revenue Trend in 2017 Market Realist
08:10AM  Drug approvals bounce back as R&D labs churn out new winners Reuters
07:36AM  Kyprolis Could Significantly Drive Amgens Revenue Growth in 2017 Market Realist
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALTIMORE DAVIDDirectorMay 31Sale153.933,700569,54131,159Jun 02 07:21 PM
Patton Cynthia MSVP & CCOMay 24Sale154.402,922451,16421,292May 24 07:35 PM
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM